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One strategy for enhancing the establishment of probiotic bacteria in the human intestinal tract is via the parallel administration
of a prebiotic, which is referred to as a synbiotic. Here we present a novel method that allows a rational selection of putative pro-
biotic strains to be used in synbiotic applications: in vivo selection (IVS). This method consists of isolating candidate probiotic
strains from fecal samples following enrichment with the respective prebiotic. To test the potential of IVS, we isolated bifidobac-
teria from human subjects who consumed increasing doses of galactooligosaccharides (GOS) for 9 weeks. A retrospective analy-
sis of the fecal microbiota of one subject revealed an 8-fold enrichment in Bifidobacterium adolescentis strain IVS-1 during GOS
administration. The functionality of GOS to support the establishment of IVS-1 in the gastrointestinal tract was then evaluated
in rats administered the bacterial strain alone, the prebiotic alone, or the synbiotic combination. Strain-specific quantitative
real-time PCR showed that the addition of GOS increased B. adolescentis IVS-1 abundance in the distal intestine by nearly 2 logs
compared to rats receiving only the probiotic. Illumina 16S rRNA sequencing not only confirmed the increased establishment of
IVS-1 in the intestine but also revealed that the strain was able to outcompete the resident Bifidobacterium population when pro-
vided with GOS. In conclusion, this study demonstrated that IVS can be used to successfully formulate a synergistic synbiotic
that can substantially enhance the establishment and competitiveness of a putative probiotic strain in the gastrointestinal tract.
The mechanistic role of the gastrointestinal (GI) microbiotaand its metabolites in maintaining human health has been well
demonstrated (1–3). Gut microbes provide several important
benefits for their host, including provision of nutrients, develop-
ment and maturation of the immune system, and protection
against pathogens via colonization resistance (4). However, the
gut microbiota may also contribute to obesity, inflammatory and
autoimmune diseases, and other chronic disease states (5–7). Such
diseases are often associated with compositional alterations in the
fecal microbiota, a condition referred to as “dysbiosis” (8). Given
that the presence of specific types of bacteria and their relative
abundance within the gut are considered to affect host health,
there is much interest in devising strategies that modulate gut
microbiota composition and potentially redress disease-related
dysbiotic patterns (9).
Dietary approaches currently available to modulate the gut mi-
crobiota include prebiotics (10–12), fermentable fibers (13, 14),
probiotics (or live biotherapeutics) (15), and synbiotics, which are
a combination of a probiotic and a prebiotic (11, 16). According to
Kolida and Gibson (16), synbiotics can be either complementary
or synergistic. Complementary synbiotics consist of a probiotic
and a prebiotic selected to independently confer benefits to the
host. In contrast, synergistic synbiotics are comprised of a pre-
biotic chosen specifically for the selected probiotic to stimulate its
growth, activity, and survival in the gastrointestinal tract (16).
Synergistic synbiotics therefore hold the potential to improve
the establishment of a specific bacterial strain when introduced
into the gastrointestinal tract. Unfortunately, successful synergis-
tic synbiotic combinations are not well established in the literature
despite a large number of studies. To our knowledge, only two
reports describe a synbiotic combination in which the prebiotic
significantly enhanced the stability, persistence, or metabolic ac-
tivity of a specific probiotic strain in vivo (17–19). As noted by
Kolida and Gibson (16), this low success rate may be explained by
the selection of most synbiotic combinations on an arbitrary basis,
including shelf life, industrial performance, availability, and cost.
Indeed, few synbiotic preparations are formulated based on a ra-
tional selection of both the prebiotic and the probiotic (12, 16),
such as via in vitro or in vivo screens assessing the ability of the
probiotic to utilize the prebiotic (17–21). Even if synbiotic formu-
lations were based on these criteria, synergism between the probi-
otic strain and the prebiotic was rarely observed in human and
animal trials (22–24). These observations suggest that the probi-
otic strains were unable to utilize the selected prebiotic to expand
their populations under the prevailing ecological conditions in the
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gastrointestinal tract. We therefore propose that synergistic syn-
biotics are likely to be more successful if selection of the probiotic
organism is based on ecological criteria.
In this report, we introduce the concept of in vivo selection
(IVS) to identify putative probiotic strains with enhanced ecolog-
ical performance when used in synbiotic applications. The con-
cept consists of isolating putative probiotic strains from fecal or
intestinal samples after enriching for them with dietary adminis-
tration of the prebiotic. We reasoned that such strains would likely
be able to successfully utilize the prebiotic in vivo within the con-
straints of the competitive gastrointestinal environment. To test
IVS, we isolated bifidobacteria from fecal samples of human indi-
viduals who had consumed the prebiotic galactooligosaccharide
(GOS) during a previous human trial (25). A combination of ap-
proaches was used to select a candidate probiotic strain (Bifido-
bacterium adolescentis strain IVS-1) enriched by GOS in vivo. We
then tested the synergistic potential of this strain and GOS when
administered as a synbiotic combination in a rat model of high-
fat-diet-induced nonalcoholic fatty liver disease (NAFLD). A
NAFLD model without severe inflammatory disease was chosen,
as inflammation would potentially confound the ecological anal-
ysis due to its effects on gut microbiota composition. Although no
direct physiological benefits were observed in the rats, the results
from the gut microbiota analysis demonstrated that IVS can be
used to select a synergistic synbiotic combination that substan-
tially increases the ecological performance of the bacterial strain in
vivo.
MATERIALS AND METHODS
Isolation of in vivo-enriched bifidobacteria from humans. In a previous
study (25), fecal samples were collected from subjects who consumed
cumulative doses of GOS (0, 2.5, 5, and 10 g per day for 3 weeks each).
Throughout the study, fresh fecal samples were collected and immediately
plated onto Rogosa LS agar to enumerate bifidobacteria. Bacterial counts
were used to identify GOS responders (i.e., individuals who experienced
significant increases in numbers of bifidobacteria), and colonies were
picked during the period in which 10 g GOS day1 was consumed. Colo-
nies were purified by successive liquid and plate cultures, and stock cul-
tures were prepared and stored at 80°C. A total of 28 individual colonies
(2 to 3 per subject) were propagated. To classify isolates, DNA was ex-
tracted by using the phenol-chloroform extraction method (26), and the
16S rRNA gene was amplified by using the 8F and 1391R universal prim-
ers. The amplification product was purified (QIAquick PCR purification
kit; Qiagen Inc., MD) and sequenced by a commercial provider (Eurofins
MWG Operon, Huntsville, AL). Identity was determined by comparing
sequences to sequences in the GenBank database; species were assigned
based on the best match.
In vitro growth on GOS. Each isolate was screened for its ability to use
GOS as a growth substrate in an MRS broth culture. Growth experiments
were performed with basal MRS broth containing 2% (wt/vol) glucose or
GOS (Purimune; GTC Nutrition, Golden, CO). The latter contained 92%
GOS, with residual carbohydrates being mainly lactose. Control cultures
were therefore also grown on basal MRS broth supplemented with the
same amount of lactose as that present in the commercial GOS (giving a
final concentration of 0.16% lactose). Cultures were incubated anaerobi-
cally at 37°C, and growth was determined by optical density measurement
at 600 nm. Strains that grew on GOS to cell densities similar to those on
glucose were considered GOS fermenters.
Strain-specific primer design and validation. The genome of B. ado-
lescentis IVS-1 was sequenced to draft status by using a standard shotgun
library prep kit on a Roche GS FLX sequencer at the former Core for
Applied Genomics and Ecology (CAGE) (University of Nebraska, Lin-
coln, NE). Sequencing resulted in 65,460 reads that were assembled de
novo by using the gsAssembler (Newbler) module of the GS-FLX Off-
Instrument software suite. This resulted in draft sequences of 148 contigs
with 15-fold coverage.
Unique genes in B. adolescentis IVS-1 were identified by comparing the
annotated genome with other available B. adolescentis genomes in the JGI
database (using the Phylogenetic Profiler for Single Genes tool in IMG).
From this analysis, the clustered regularly interspaced short palindromic
repeat (CRISPR)-associated helicase Cas3 was selected as the target gene,
and a putative primer pair was designed by using Primer 3 software (27).
Candidate primers were evaluated for hairpin and dimer formation by
using Netprimer (Premier Biosoft International, Palo Alto, CA). The se-
lected forward (F) primer TTGCTTTTGCTCTGGAACATAC and reverse
(R) primer GTAATGAGGTAATACTGCGTCC were validated in silico by
performing a BLAST search against the NCBI database. These primers
were also validated experimentally by quantitative real-time PCR (qRT-
PCR) using DNA from 10 different Bifidobacterium strains related to
strain IVS-1 (each having 96% identity at the 16S rRNA gene level).
These strains included Bifidobacterium adolescentis ATCC 15703, Bifido-
bacterium adolescentis L2-32, Bifidobacterium longum subsp. longum
ATCC 15707, Bifidobacterium longum DJO10A, Bifidobacterium longum
ATCC 15697, Bifidobacterium longum subsp. longum F8, Bifidobacterium
longum subsp. longum JDM301, Bifidobacterium sp. strain 113, Bifidobac-
terium sp. strain 12_1_47BFAA, and Bifidobacterium sp. strain HMLN14.
Furthermore, to test if primers could select against fecal bacterial commu-
nities in both humans and rats, DNA from 23 human fecal samples and 10
Sprague-Dawley rat fecal samples from an independent study were tested.
Human fecal materials analyzed included the baseline samples (i.e.,
before GOS supplementation) from 18 subjects from a previous study
by Davis et al. (25) as well as five other human fecal samples from an
independent study.
Quantitative real-time PCR. qRT-PCR was performed by using a
Mastercycler Realplex2 instrument (Eppendorf AG, Hamburg, Ger-
many). Each PCR was performed with 25-l volumes using real-time
master mix containing SYBR (5 Prime Inc., Gaithersburg, MD) and either
genus-specific primers for Bifidobacterium, F primer TCGCGTC(C/T)G
GTGTGAAAG and R primer CACATCCAGC(A/G)TCCAC (25, 26), or
the strain-specific primers for B. adolescentis IVS-1 (described above),
each at a concentration of 0.8 M. Annealing temperatures of 58°C and
61°C were used for the genus- and strain-specific PCRs, respectively. Stan-
dard curves for absolute quantification of bacterial cell numbers were
prepared by using cultures of B. adolescentis IVS-1 grown overnight (14
h), as described previously (25, 26).
Administration of the probiotic, prebiotic, and synbiotic to rats. A
freeze-dried powder of Bifidobacterium adolescentis IVS-1 was produced
by a contract manufacturer (Culture Systems, Mishawaka, IN). The pow-
der contained 5  1010 CFU g1 and was stable during the entire course of
the study. For delivery to the rats, the powder was suspended in drinking
water (double-distilled water) to reach a concentration of 3  107 cells
ml1. GOS was diluted in water at a concentration of 0.033 g ml1, and
the synbiotic was prepared by mixing both IVS-1 and GOS in the above-
mentioned concentrations. All preparations were prepared fresh daily in
drinking water for the duration of the experiment. Cell viability and sta-
bility were validated by plating samples on MRS medium at different time
points. This analysis revealed that IVS-1 was highly stable in drinking
water, with levels dropping 1 log over 24 h. The addition of GOS did not
influence the viability of the probiotic in drinking water (data not shown).
Rat study design. Synergism of the synbiotic preparation was tested in
a rat model of NAFLD (28). Four-week-old male Sprague-Dawley rats
were obtained from Charles River Laboratories (Wilmington, MA) and
acclimated for 5 days prior to study initiation. All animals were housed in
pairs in individually vented cages mounted on a rack with positive airflow.
The room environment was maintained at 20°C to 21°C with a 12-h light-
dark cycle. Prior to the start of the study, all rats received a standard rat
chow and autoclaved, double-distilled water ad libitum during the 5-day
Krumbeck et al.
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acclimation period. All animal procedures were approved by University of
Nebraska—Lincoln IACUC.
Rats were randomly assigned to one of five treatments, with three to six
rats per group. Groups 1 through 4 were fed a high-fat diet (60% kcal from
fat) (AIN-58G9 TestDiet) (see Table S1 in the supplemental material),
while group 5 received a standard diet (12% fat) (AIN-58G7 TestDiet) for
8 weeks. After 4 weeks of feeding, groups were assigned to one of the
following supplement treatments. Rats in groups 1 and 5 received no
additional treatment. Group 2 rats received drinking water supplemented
with 3.3% GOS to give 1 g of GOS day1 rat1. Group 3 rats were given
drinking water supplemented with 1  109 CFU of B. adolescentis IVS-1
day1 rat1. Group 4 rats received both the GOS and IVS-1 (synbiotic
mixture), at the same doses as those given to groups 2 and 3. All treat-
ments were prepared fresh daily and administered for 4 weeks. The daily
water intake per rat was significantly different among groups and was used
to calculate the absolute doses of probiotic cells per day (P  0.001) (see
Table S2 in the supplemental material). Rats fed the probiotic drank sig-
nificantly more water (41.9 	 8.6 ml) than did rats fed the synbiotic
(35.4 	 4.5 ml), resulting in a significantly higher dose of IVS-1 in the
probiotic group (1.26  109 CFU versus 1.06  109 CFU; P  0.0001).
GOS consumption was not significantly different between the prebiotic-
and synbiotic-fed groups (P  0.2063) (see Table S2 in the supplemental
material).
Body weights were determined weekly throughout the study. All rats
were necropsied after 8 weeks of study. Blood, cecum, colon content, liver,
and epididymal fat pads were collected, and the cecum and colon content
were immediately frozen in liquid nitrogen and stored at 80°C until
further use.
Evaluation of host physiological parameters in rats. Liver lipid ex-
traction was performed according to methods described previously by
Folch and colleagues (29). Aliquots of lipid extract were saponified to
quantify triglycerides (TGs) by using the TG diagnostic kit (Thermo di-
methyl adipimidate kit; Thermo Electron Clinical Chemistry, Louisville,
CO). Data are reported as g TG mg1 (wet weight) liver tissue. To
evaluate liver damage, plasma alanine aminotransferase (ALT) and alka-
line phosphatase (ALP) enzyme levels were measured, which are indica-
tors of hepatocyte damage/leakage and cholangiocyte stress, respectively
(30, 31). Blood was collected into heparinized tubes at necropsy, and ALT
and ALP levels were quantified by using a Mammalian Liver Profile rotor
in a VetScan VS2 analyzer (Abaxis, Union City, CA). Levels of tumor
necrosis factor alpha (TNF-
) and monocyte chemoattractant protein 1
(MCP-1) were quantified as measures of systemic inflammation by using
a Milliplex rat magnetic bead multiplex assay (Merck Millipore, Billerica,
MA) according to the manufacturer’s protocol.
Illumina 16S RNA sequencing and sequence analysis. Colonic and
cecal contents were flash-frozen in liquid nitrogen at necropsy, and DNA
was extracted as described previously (26), with one modification: the
lysis buffer contained 20 mM Tris-HCl (pH 8), 2 mM EDTA, 1.2% Triton
X-100 (pH 8.0), and 20 mg ml1 Lysozyme (MP Biomedicals, Solon,
OH). Amplicon sequencing of colonic contents was performed by the
University of Minnesota Genomics Center, and all samples were se-
quenced together in the same run. First, the V5-V6 region of the 16S rRNA
gene was amplified with primer pair 784F (5=-RGGATTAGATACCC-3=)
and 1064R (5=-CGACRRCCATGCANCACCT-3=) in a 25-l PCR mix-
ture containing 5 l of template DNA, 5 l of 2 HotStarTaq PCR master
mix, a final concentration of primers of 500 nM, and 0.025 U l1 Hot-
StarTaq polymerase (Qiagen Inc.). Amplification reactions included an
initial denaturation step at 95°C for 5 min followed by 20 to 25 cycles of
denaturation (50 s at 94°C), annealing (30 s at 40°C), and elongation (30
s at 72°C). Next, samples were diluted 1:100 in water for input into library
tailing PCR. The PCR was analogous to the one conducted for initial
amplification except for a Taq polymerase concentration of 0.25 U l1,
and the PCR conditions consisted of an initial denaturation step at 95°C
for 5 min followed by 10 to 15 cycles of denaturation (50 s at 94°C),
annealing (30 s at 40°C), and elongation (1 min at 72°C).
PCR products were quantified by using the Quant-iT PicoGreen dou-
ble-stranded DNA (dsDNA) assay kit (Life Technologies). A subset of the
amplicon libraries was spot checked on a Bioanalyzer High-Sensitivity
DNA chip (Agilent Technologies, Santa Clara, CA) for correct amplicon
size. Next, samples were normalized to 2 nM and pooled. The total vol-
ume of the libraries was reduced by the use of a SpeedVac, and amplicons
were size selected at 420 bp 	 20% by using the Caliper XT system
(PerkinElmer, Waltham, MA). Afterwards, library pools were cleaned
with 1.8 AMPureXP beads (Beckman Coulter, Brea, CA) and eluted in
water. The amount of DNA in the final pool was quantified with PicoGreen
and normalized to 2 nM for input into the Illumina MiSeq platform (v3
kit) to produce 300-bp paired-end sequencing products. Clustering was
done at 10 pM with a 5% spike of PhiX. The generated sequences were
quality filtered with Illumina software at the University of Minnesota
Genomics Center. Twenty-two of 24 samples met all quality control cri-
teria and were used for the microbial community analysis.
Microbial community analysis. Reads were trimmed to 240 bp with
the FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/), and paired-
end reads were merged with the merge-illumina-pairs application (https:
//github.com/meren/illumina-utils/) (P value of 0.03, enforced Q30
check, perfect matching to primers, and no ambiguous nucleotides al-
lowed). Files exceeding 30,000 reads were subsampled to this number in
Mothur v.1.31.162 to standardize the sequencing depth across samples.
Subsequently, USEARCH v7.0.100163 was used to generate operational
taxonomic units (OTUs) with a 98% similarity cutoff. OTU generation
included the removal of putative chimeras identified against the Gold
reference database, in addition to the chimera removal inherent to the
OTU clustering step in UPARSE. After quality control and chimera re-
moval, samples contained an average of 25,718 	 941 sequences. The
resulting sequences were also taxonomically characterized from phylum
to genus levels with Ribosomal Database Project (RDP) Classifier with the
MultiClassifier v1.1 tool. All phylotypes were computed as percent pro-
portions based on the total number of sequences in each sample.
Statistical analysis. Results are expressed as means 	 standard devi-
ations (SD) unless otherwise stated. To analyze bacterial composition,
diversity differences, and host physiological parameters, one-way analyses
of variance (ANOVA) with repeated measures in combination with
Tukey’s post hoc tests were applied. To achieve normality for data that
were not normally distributed, values were subjected to log10 transforma-
tions. If only two groups were compared, Student’s t tests were performed.
Spearman’s correlations were used to assess correlations between bacterial
groups. To account for type I errors, the false discovery rate was used. A P
value of 0.05 and correlation coefficient (r) values of 0.60 (in absolute
values) were considered significant. Analyses of variance and false discov-
ery rate control were performed by using SAS/STAT (SAS Institute Inc.,
Cary, NC, USA), while correlations were determined by using GraphPad
Prism version 5.0 (GraphPad Software, La Jolla, CA, USA).
Nucleotide sequence accession number. The genome sequence of B.
adolescentis IVS-1 has been deposited in the DDBJ/EMBL/GenBank data-
base under accession number JRNZ01000000.
RESULTS
In vivo selection of B. adolescentis IVS-1. In a previous study (25,
32), we reported a significant and remarkably specific enrichment
of Bifidobacterium populations in human subjects during dietary
supplementation with GOS (as demonstrated by 454 sequencing,
genus-specific qRT-PCR, and quantitative culture), which is in
agreement with data from other GOS feeding studies (33–38).
Cultural enumeration of fecal samples during the human trial
allowed us to identify individuals in which bifidobacteria were
enriched by GOS and from whom strains likely to utilize GOS in
vivo could be selected. This novel strategy for selection and recov-
ery of autochthonous strains enriched by a prebiotic is referred to
as in vivo selection (IVS) (Fig. 1A). Using the IVS approach, a total
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of 28 presumptive bifidobacterial colonies from 11 subjects were
isolated and classified by sequencing of the 16S rRNA genes. Eight
isolates were classified as Bifidobacterium adolescentis, eight were
classified as Bifidobacterium longum, three were classified as Bifi-
dobacterium pseudocatenulatum, and one was classified as Bifido-
bacterium bifidum. Of the remaining isolates, four belonged to the
Coriobacterium genus, one could be classified only to the family
level (Lachnospiraceae), and three could not be sequenced due to
insufficient growth. All strains resulting in pure cultures were also
screened for their ability to ferment GOS during in vitro growth,
and 13 were classified as GOS fermenters, 12 were classified as
nonfermenters, and 3 could not be propagated to be tested (data
not shown). Out of the 13 strains able to ferment GOS, 5 were
classified as B. longum, 5 were classified as B. adolescentis, 1 was
classified as B. bifidum, 1 was classified as B. pseudocatenulatum,
and another one was classified as Lachnospiraceae. None of the
isolated Coriobacterium strains were classified as fermenters.
Based on the culture data, 454 sequencing (32), and the GOS
fermentation tests, we selected one strain and designated it IVS-1.
This strain originated from a subject who showed a strong bifido-
genic response to GOS (Fig. 1B). Based on 16S rRNA sequencing,
IVS-1 had 98.4% identity (100% query coverage and an E value of
zero) with the 16S rRNA gene of B. adolescentis ATCC 15703T and
was therefore allotted to this species. However, the strain belongs
to a distinct phylogenetic cluster (Bifidobacterium species II clus-
ter) detectable by using the V1-V3 region of the 16S rRNA gene
(32). This cluster was significantly enriched by GOS in all subjects,
including the individual from whom IVS-1 was isolated (Fig. 1C).
The ability of B. adolescentis IVS-1 to utilize GOS was demon-
strated by growth in MRS broth containing 2% GOS (see Fig. S1 in
the supplemental material). The established metabolic benefits of
the species B. adolescentis serve as another rationale for the selec-
tion of IVS-1 for future applications (39, 40).
To verify that B. adolescentis strain IVS-1 was specifically en-
riched by GOS in vivo, we devised a strain-specific qRT-PCR ap-
proach with primers based on the genome sequence of IVS-1.
Primer specificity was validated against 10 closely related Bifido-
bacterium strains, fecal DNA from all subjects included in the
human feeding trial (25) and five additional human individuals,
and 10 fecal samples from Sprague-Dawley rats from an indepen-
dent experiment. A detectable PCR product was obtained only
with DNA from B. adolescentis IVS-1 and the fecal sample from
which the strain was isolated. This finding indicated that the prim-
ers were highly strain specific and that strain IVS-1 was present
only in the human subject from whom it was isolated.
The strain-specific qRT-PCR system was then used to quantify
the abundance of IVS-1 in fecal samples from this subject during
the GOS feeding study. This analysis revealed that IVS-1 levels
were increased 8-fold during both the 5-g and 10-g GOS dose
periods compared to the 0-g period (P  0.001) (Fig. 1D), before
returning to baseline levels immediately after GOS consumption
ended. Collectively, these results demonstrated the utility of IVS
to select a bacterial strain enriched in the human gastrointestinal
tract through dietary administration of a prebiotic.
FIG 1 In vivo selection to identify putative probiotic strains to be used in synbiotic applications. (A) Concept of in vivo selection. (B) Proportion of fecal
bifidobacteria in a human individual consuming GOS (included in chews) in four increasing doses (0, 2.5, 5, and 10 g) during a human feeding trial (25), as
determined by 454 pyrosequencing of 16S rRNA tags. (C) Proportion of Bifidobacterium lineage species II in the same individual, as determined by pyrose-
quencing. (D) Cell numbers of B. adolescentis IVS-1 in the same individual, as quantified by strain-specific qRT-PCR.
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Test of the synbiotic combination using rats on a high-fat
diet. We systematically tested synergism between strain IVS-1 and
GOS when used as a synbiotic in rats fed a high-fat diet (Fig. 2A).
Decreases in numbers of bifidobacteria are often observed during
high-fat-diet feeding (41–43). To determine if our synbiotic strat-
egy could redress this decrease, we employed a rat model of high-
fat-diet-induced NAFLD where rats develop steatosis (fatty liver)
but do not show an increase in body weight, develop liver inflam-
mation, or progress to nonalcoholic steatohepatitis (NASH) (28).
In our study, all high-fat-diet-fed rats developed steatosis (i.e.,
liver triglyceride levels of 50 g mg1 of tissue) and had slightly
increased plasma ALP levels compared to rats fed a standard diet
(see Table S2 in the supplemental material). Dietary supplements
significantly influenced triglyceride liver contents; however, high-
fat-diet-fed rats did not develop the histopathological liver in-
flammation characteristic of NASH (data not shown) and did not
have increased plasma ALT levels (see Table S2 in the supplemen-
tal material). Plasma tumor necrosis factor alpha (TNF-
) and
monocyte chemoattractant protein 1 (MCP-1) levels were not sig-
nificantly elevated in the high-fat-fed rats compared to the con-
trols (see Table S2 in the supplemental material), indicating a lack
of systemic inflammation. Together, these data indicated that all
rats receiving a high-fat diet developed NAFLD but not severe
inflammatory disease that would confound the evaluation of syn-
biotic synergy and gut microbial ecology.
Experiments in rats demonstrate strong synergism between
IVS-1 and GOS. To test the functionality of the prebiotic to sup-
port the establishment of B. adolescentis IVS-1 in the rat intestine,
rats fed a high-fat diet were administered either IVS-1 alone, GOS
alone, or the synbiotic combination; all findings were compared to
results for the high-fat controls (Fig. 2A). Consistent with data from
previous studies (41, 42), high-fat feeding decreased the abundance of
bifidobacteria in both the colon and cecum of the rats, although this
reduction did not reach statistical significance (Fig. 2B and Table 1).
Genus-specific qRT-PCR analysis revealed that the prebiotic, but not
IVS-1, significantly increased the total number of bifidobacteria in
the cecum (Fig. 2B). These findings indicate that the introduction of
IVS-1 alone did not increase Bifidobacterium abundance above
baseline levels (108 cells/g), whereas the prebiotic substrate was
able to support the resident population. Compared to IVS-1 and
GOS alone, the combination of the two dramatically increased the
total number of bifidobacteria in the cecum (P  0.01 between
synbiotic and prebiotic treatments; P  0.001 between synbiotic
and probiotic treatments) (Fig. 2B).
Strain-specific qRT-PCR analysis of B. adolescentis IVS-1
clearly demonstrated a synergistic effect of IVS-1 and GOS in the
colon and in the cecum. Even though rats receiving IVS-1 alone
consumed significantly more IVS-1 on a daily basis than did rats
given the synbiotic due to increased drinking water consumption
(P  0.0001) (see Table S2 in the supplemental material), the
synbiotic led to an almost 2-log increase in the level of IVS-1 in the
colon and cecum (9.47 	 0.2 log10 cells g
1 and 9.43 	 0.2 log10
cells g1, respectively) compared with the probiotic treatment
(7.9 	 0.1 and 7.44 	 0.3 log10 cells g
1 in the cecum and colon,
respectively) (P  0.0001) (Fig. 2C). No IVS-1 was detected in rats
fed the standard diet, the high-fat diet, or the prebiotic alone.
16S rRNA sequencing confirms synergism between IVS-1
and GOS in vivo. We analyzed the 16S rRNA tags obtained via
FIG 2 Test of a synbiotic combination of B. adolescentis IVS-1 and GOS in a high-fat-diet rat model. (A) Experimental design of the rat study. Rats were fed either
a standard diet or a high-fat diet for 8 weeks, supplemented with or without a probiotic (IVS-1), a prebiotic (GOS), or a synbiotic (IVS-1 plus GOS) for the last
4 weeks. (B) Quantification of absolute cell numbers of bifidobacteria in colonic and cecal contents by genus-specific qRT-PCR. (C) Strain-specific qRT-PCR was
used to quantify absolute numbers of B. adolescentis IVS-1 in colonic and cecal contents.
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Illumina sequencing to gain a community-wide perspective on
treatment effects on the resident gut microbiota. The ability of
pro- and synbiotic treatments to establish IVS-1 in rats was as-
sessed based on the abundance of an operational taxonomic unit
(OTU) representing the species B. adolescentis (OTU_2). This spe-
cies was undetectable in rats that did not receive the probiotic
treatment but constituted 3.4% of the microbiota in rats fed IVS-1
(Fig. 3A and Table 1). This finding indicates that the B. adolescentis
population observed in rats was due solely to the administration of
IVS-1. This finding was expected, as this species is not a member of
the normal rat microbiota. Sequences representing B. adolescentis
were enriched to 37.0% in rats receiving the synbiotic treatment,
indicating a significant enhancement of the probiotic (in terms of
abundance) due to the addition of the prebiotic (P  0.0159).
Without GOS, IVS-1 was only the eighth most abundant OTU in
the rats’ colonic microbiota, while it became the most abundant
OTU when given together with GOS, having an abundance almost
four times higher than that of the second most abundant OTU (a
Blautia species, at 9.7%) (Fig. 3A). This finding demonstrated that
IVS-1 could be introduced as the dominant member of the rat gut
microbiota when GOS was also provided.
Community-wide characterization of effects on gut micro-
biota. GOS treatment alone promoted a remarkably specific bifi-
dogenic response, leading to an increase in the abundance of only
one OTU related to Bifidobacterium pseudolongum (OTU_6) (Ta-
ble 1 and Fig. 3A). These findings confirm the highly specific bifi-
dogenic response of GOS, which was previously demonstrated in
humans (32).
Although IVS-1 treatment alone did not significantly increase
the abundance of the genus Bifidobacterium, it induced a signifi-
cant increase in the abundance of Bifidobacterium adolescentis at
the species level (Table 1). Of note, several unexpected changes
were also detected, such as enrichment of the family Clostridi-
aceae, the genus Clostridium, and an OTU within this genus
(OTU_9). Furthermore, the abundance of an OTU related to Lac-
tobacillus intestinalis (OTU_33) increased, while that of an OTU
related to Lactococcus lactis (OTU_1) decreased (Table 1).
Synbiotic treatment significantly increased the proportion of
Actinobacteria (P  0.0001), the family Bifidobacteriaceae (P 
0.0017), and the genus Bifidobacterium (P  0.0017) (Table 1).
These shifts were almost completely equivalent to shifts of
OTU_2, showing that the above-described alterations at higher
TABLE 1 Proportions of bacterial taxa significantly influenced by dietary treatments
Taxonomic group
Mean % bacterial abundance 	 SDc
P value
determined by
ANOVA
Standard
diet
Control
HF diet
Prebiotic
(HF)
Probiotic
(HF)
Synbiotic
(HF)
Phyla
Firmicutes 87.6 	 5 A 88.8 	 9 A 76.9 	 8 A 87.8 	 5 A 59.3 	 7 B 0.0001
Actinobacteria 8.9 	 6 AB 3.6 	 2 A 19.6 	 8 BC 7.6 	 4 A 39.1 	 7 C 0.0001
Families
Clostridiaceae 3.9 	 6 0.5 	 1 0.8 	 1 5.4 	 6 A 0.2 	 0 B 0.0061
Incertae sedis XIV 3.7 	 6 7.5 	 10 11.0 	 15 1.1 	 2 A 17.3 	 12 B 0.0342
Streptococcaceae 12.7 	 5 21.3 	 5 A 9.3 	 1 8.9 	 6 B 6.6 	 2 B 0.0045
Erysipelotrichaceae 16.8 	 11 21.3 	 17 9.2 	 1 A 26.5 	 10 B 8.3 	 3 A 0.0226
Bifidobacteriaceae 5.9 	 7 A 1.3 	 1 A 17.0 	 9 4.1 	 2 A 37.8 	 7 B 0.0017
Coriobacteriaceae 0.6 	 0 0.3 	 0 1.0 	 1 1.9 	 3 A 0.2 	 0 B 0.0263
Rikenellaceae 0.9 	 1 A 0.1 	 0 0.3 	 0 0.1 	 0 0.0 	 0 B 0.0181
Genera
Clostridium 3.9 	 6 0.5 	 1 A 0.8 	 1 5.3 	 6 B 0.2 	 0 A 0.0122
Blautia 3.4 	 6 7.4 	 10 11.0 	 15 0.9 	 1 A 17.2 	 12 B 0.0431
Holdemania 0.1 	 0 1.0 	 2 A 0.9 	 0 0.0 	 0 B 0.0 	 0 B 0.0117
Bifidobacterium 5.9 	 7 A 1.3 	 1 A 17.0 	 9 4.1 	 2 A 37.8 	 7 B 0.0017
Lactococcus 12.4 	 4 21.0 	 5 A 9.1 	 1 8.7 	 6 B 6.3 	 2 B 0.0045
Alistipes 0.9 	 1 A 0.1 	 0 0.3 	 0 0.1 	 0 0.0 	 0 B 0.0181
OTUsa
OTU_2 (B. adolescentis, 99%) 0.0 	 0 A 0.0 	 0 A 0.0 	 0 A 3.4 	 2 BC 37.0 	 7 BD 0.0001
OTU_1 (L. lactis, 100%) 12.4 	 4 21.0 	 5 A 9.1 	 1 8.6 	 6 B 6.3 	 2 B 0.0045
OTU_626 (Lachnospiraceaeb) 0.4 	 1 A 0.1 	 0 A 0.0 	 0 B ND 0.1 	 0 0.0002
OTU_7 (Turicibacter sanguinis, 97%) 3.7 	 3 2.3 	 3 2.3 	 2 9.1 	 7 A 0.5 	 1 B 0.0279
OTU_14 (Blautiab) 0.0 	 0 A 0.1 	 0 AB 1.5 	 1 BC 0.0 	 0 AB 9.7 	 6 CD 0.0003
OTU_33 (L. intestinalis, 99%) ND 0.0 	 0 A ND 1.1 	 2 B 0.0 	 0 A 0.0022
OTU_9 (Clostridium sp.b) 3.8 	 6 0.5 	 1 A 0.7 	 1 5.3 	 6 B 0.2 	 0 A 0.0128
OTU_6 (B. pseudolongum, 97%) 5.8 	 7 0.9 	 1 16.6 	 8 A 0.6 	 1 0.0 	 0 B 0.0293
OTU_44 (Clostridium cocleatum, 99%) ND 1.0 	 1 A ND 0.0 	 0 B ND 0.0121
a Percent homologies to the closest type strain in the database are shown in parentheses. If the strain could not be assigned to a type strain (97% homology), RDP Classifier was
used to determine the most likely genus, and the RDP Classifier value is shown (80% cutoff).
b OTU without closely related type strain (97% homology) classified with RDP Classifier.
c Values with different uppercase letters are significantly different from each other. HF, high fat; ND, not detected.
Krumbeck et al.
2460 aem.asm.org April 2015 Volume 81 Number 7Applied and Environmental Microbiology
  
taxonomic levels were due to the enrichment of IVS-1. The
establishment of IVS-1 was associated with an increase in the
abundances of the genus Blautia and one OTU within this genus
(OTU_14). In addition, there was a reduction in the abundances
of the phylum Firmicutes (P  0.0001) and families within this
phylum, including Clostridiaceae, Streptococcaceae, and Erysipelo-
trichaceae. The abundances of the genera Clostridium and Lacto-
coccus and OTUs within these genera were also decreased (Ta-
ble 1).
To assess both the alpha and beta diversities of the community
in the colon, different diversity indexes were calculated from the
data. Specifically, Shannon’s index and the number of observed
OTUs were used to determine the alpha diversity, and principal
coordinate analysis (PCoA) and nonmetric multidimensional
scaling (NMDS) plots based on Bray-Curtis distance were used to
visualize the similarity between samples for each treatment.
On average, 135.41 	 34.4 OTUs per sample were identified.
Alpha diversity based on Shannon’s index was not significantly
influenced by the treatment; however, there was a tendency for
reduced diversity in the synbiotic group. This was caused by a
slight reduction in community evenness, likely due to the expan-
sion of a single species (B. adolescentis) (data not shown). Two
independent approaches were used to analyze the beta diversity of
the microbiota communities among treatments. PCoA and
NMDS, based on Bray-Curtis distances of beta diversity, revealed
that communities from rats fed the synbiotic clustered separately
from the microbiomes of rats fed all the other treatments, which
clustered together (Fig. 3B and C). This finding demonstrated that
only the synbiotic treatment caused a global shift in microbiota
structure.
Systematic analyses of associations between members of the
gut microbiota. To identify potential interactions between IVS-1
FIG 3 Characterization of the rat colonic microbiota composition by Illumina sequencing of 16S rRNA tags. (A) Analysis of colonic microbiota at the OTU level.
OTUs representing at least 1% of total sequences are shown individually, while OTUs representing 1% are grouped. OTUs in colors other than light blue were
significantly influenced by the dietary treatment. (B) Principal coordinate analysis (Bray-Curtis distance) of beta diversity. (C) NMDS plot of beta diversity based
on Bray-Curtis distance. SD, standard diet.
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and members of the gut microbiota, and among other bacterial
members, we performed correlation analyses on all taxon combi-
nations in the data set. Correlations were performed by using bac-
terial abundance data from all treatments. Strong negative corre-
lations between the family Bifidobacteriaceae and the family
Clostridiaceae (Fig. 4A), the genera Bifidobacterium and Lactococ-
cus (Fig. 4B), and the genera Bifidobacterium and Akkermansia
(Fig. 4C) were observed. In addition, strain IVS-1 levels (OTU_2)
showed a negative correlation with Lactococcus lactis (Fig. 4D) and
a very tight negative association with resident B. pseudolongum
(r  0.64; P  0.0004) (Fig. 4E). These negative associations
suggest direct or indirect competition between these bacterial
taxa. Positive associations between both Bifidobacteriaceae and Bi-
fidobacterium and the genus Blautia were detected, suggesting a
synergistic relationship, which may be supported by the addition
of GOS (Table 1 and Fig. 4F).
DISCUSSION
Synergistic synbiotics are a promising concept to modulate the
composition of the gut microbiota and promote the establish-
ment of probiotic organisms in the gut (16). Despite this po-
tential, however, there are few in vivo human or animal studies
providing evidence that prebiotics can be used to support spe-
cific probiotic strains. Unfortunately, most synbiotic studies,
including work in rats (44–49), mice (50–52), pigs (53–57),
chickens (58, 59), and humans (60), did not employ strain-
specific detection methods and therefore did not provide in-
formation on the potential synergism between pre- and probi-
otics. Of the in vivo studies that did discriminate the probiotic
strain, most still did not demonstrate that in vivo performance
could be enhanced by a prebiotic. This accounts for experi-
ments using synbiotic formulations in humans (61), rats (62,
63), and other animal models (64). These findings suggest that,
with few exceptions (17–19), probiotic strains are unable to
compete against the resident gut microbiota, which is inher-
ently resistant to outside colonizers (65), even when an exoge-
nous growth substrate in the form of a prebiotic is provided.
Several reasons may explain the low success rates of syner-
gistic synbiotics when evaluated in vivo, even for combinations
in which the probiotic strain is able to utilize the prebiotic
substrate in vitro. First, to become established in the gut, the
probiotic strain must be able to occupy an ecological niche.
This means that strains must not only outcompete the resident
microbiota for the prebiotic substrate but also secure other
nutrients that might be growth limiting (such as amino acids,
lipids, vitamins, minerals, and nucleotides, etc.). In addition,
probiotic strains must tolerate the prevailing environmental
conditions in the digestive tract (including pH, bile acids, IgA,
and defensins). Ultimately, in vitro tests are unable to predict
the ability of a probiotic to benefit from a prebiotic substrate
within the constraints of the competitive gastrointestinal envi-
ronment. In contrast, the IVS approach described here over-
comes many limitations of in vitro tests used to formulate syn-
biotics because it provides a basis for identifying bacterial
strains that are able to utilize the prebiotic substrate under the
same ecological conditions in which they are intended to func-
tion.
In this study, we employed IVS and selected a synbiotic com-
bination that was tested in a rat model of NAFLD. Although the
synbiotic did not influence host phenotypes, it was highly efficient
at enhancing population levels of the probiotic strain, making it
the most dominant OTU in the gut (Fig. 3A and Table 1). These
findings provide a proof of concept for the potential of in vivo
FIG 4 Correlation analysis of colonic taxa present in rats fed a high-fat diet supplemented with or without a probiotic (IVS-1), a prebiotic (GOS), or a synbiotic
(IVS-1 plus GOS) or a standard diet. Bacterial quantities are expressed as percent abundances of total bacteria as determined by 16S rRNA sequencing.
Spearman’s correlations between Bifidobacteriaceae and Clostridiaceae (A), Bifidobacterium and Lactococcus (B), Bifidobacterium and Akkermansia (C), Bifido-
bacterium adolescentis IVS-1 and Lactococcus lactis (D), Bifidobacterium adolescentis IVS-1 and Bifidobacterium pseudolongum (E), and Bifidobacterium and
Blautia (F) were determined.
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selection to identify synbiotic combinations that are, in ecological
terms, highly synergistic. In addition to enhancing the abundance
of strain IVS-1, the synbiotic used here also redressed the high-fat-
diet-induced reduction in the level of bifidobacteria detected in
rats that is often reported in the literature (41–43). Therefore,
although no metabolic benefits were seen in the rat model used in
our study, the synbiotic may be beneficial in other scenarios, as
bifidobacteria are considered health-promoting organisms (6, 26,
66–68).
The community-wide analysis provided evidence that syner-
gism between GOS and strain IVS-1 increased the competitive
fitness of the strain in the rat intestinal tract. B. pseudolongum,
which is a natural member of the rat GI tract (69), was detected in
relative abundances of 5.8% and 0.9% in rats fed the standard and
high-fat diets, respectively. Although the probiotic treatment did
not affect levels of B. pseudolongum, the prebiotic treatment in-
creased the abundance of this species to 16.6%, indicating that B.
pseudolongum utilized GOS in vivo. However, the parallel addition
of strain IVS-1 with GOS completely excluded B. pseudolongum,
and a strong negative correlation between this species and IVS-1
was observed (r  0.67; P  0.0006) (Fig. 4E). These findings
indicate that IVS-1 not only had a higher affinity for GOS in vivo
than the resident Bifidobacterium species but also utilized GOS to
increase its competitiveness and effectively outcompete a closely
related resident species. This finding is consistent with the niche
exclusion model, which states that the organism most efficient at
using limited nutrients outcompetes its competitors for the same
niche (70). Strong inverse correlations between bifidobacteria and
Clostridiaceae, Lactococcus, and Akkermansia (Fig. 4A to C) were
also observed. It is likely that these associations are also due to
niche competition and are potentially enhanced by GOS admin-
istration. Bifidobacteria produce short-chain fatty acids that are
inhibitory to other bacteria either by lowering the pH or via direct
antimicrobial effects (e.g., acetic acid) (71). In summary, these
findings demonstrate that the competitive fitness of strain IVS-1
was increased by GOS, which supports the conclusion that IVS can
select synbiotic combinations with extremely high synergism. To
what degree the increased competitive interactions between IVS-1
and the resident microbiota impact host health is difficult to pre-
dict and likely context dependent, but they clearly should be con-
sidered in future studies.
Correlation analyses revealed only one positive association
among members of the rat microbiota, between the bifidobacteria
(at the family and genus levels) and the genus Blautia. The abun-
dance of OTU_14, an uncultured Blautia strain, was also signifi-
cantly increased by GOS and in the synbiotic treatment (Table 1).
The positive correlation between Bifidobacterium and Blautia
(Fig. 4F) indicates a synergistic effect between the two taxa. The
significant increase in the abundance of Blautia in the synbiotic
treatments further suggests a syntrophic interaction between
IVS-1 and Blautia, as GOS is consumed mainly by bifidobacteria
(72), and the genus Blautia is not reported to utilize GOS. In
contrast, the genus Blautia contains bacteria that are hydro-
genotrophic acetogens, which utilize H2 and CO2 as energy
sources (73). Although bifidobacteria do not produce these gases,
cross-feeding between bifidobacteria and butyrate-producing co-
lon bacteria can result in H2 and CO2 production (74), which
might explain the positive correlations between Bifidobacterium
and Blautia. However, additional experiments are necessary to
establish the mechanism by which GOS can enhance the popula-
tions of Blautia in the gut and the positive associations between
this genus and IVS-1.
In this study, we have shown how IVS can be used to formulate
a highly synergistic synbiotic that can substantially enhance pop-
ulation levels and the competitiveness of a putative probiotic
strain in the gastrointestinal tract and establish it as the dominant
member of the gut microbiota in a conventional animal model. To
our knowledge, this has not yet been reported in the probiotic
literature. The process of IVS is broadly applicable and can easily
be extended to other host species, body sites, prebiotic substrates
(or dietary fibers), or target organisms. For example, it may be
possible to use IVS to enhance other putative health-promoting
genera such as Akkermansia, which has been shown to respond to
prebiotics in vivo (75). While we selected B. adolescentis IVS-1
during a human trial that did not determine the physiological
effect of GOS, IVS might be especially powerful when combined
with a human clinical trial that determines the beneficial effect of
a prebiotic on the host as the primary selection criterion. There-
fore, to develop synbiotics for specific health applications, the IVS
concept should be extended to select bacterial strains that not only
responded to the prebiotic but whose expansion correlated with
beneficial physiological effects for the host. Such an approach
would have the potential to identify health-promoting strains
whose metabolic activity in vivo could be increased through a pre-
biotic. This might also result in synbiotic applications with greater
health effects than those of the prebiotic alone, especially in the
subset of humans who do not respond to the prebiotic (14, 32). A
human study testing the synbiotic combination identified here
(and comparing it with a synbiotic that includes a Bifidobacterium
strain that can ferment GOS but was not selected by IVS) is cur-
rently in progress. Clearly, the application of IVS is likely to en-
hance the ecological performance of probiotic strains or live bio-
therapeutics within the habitats in which they are thought to
function, and the technology could be readily applied in the design
of microbiota-modulating therapies.
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2009. Synbiotic effect of Lactobacillus helveticus M92 and prebiotics on
the intestinal microflora and immune system of mice. J Dairy Res 76:98 –
104. http://dx.doi.org/10.1017/S0022029908003737.
51. Foye OT, Huang I-F, Chiou CC, Walker WA, Shi HN. 2012. Early
administration of probiotic Lactobacillus acidophilus and/or prebiotic in-
ulin attenuates pathogen-mediated intestinal inflammation and Smad 7
cell signaling. FEMS Immunol Med Microbiol 65:467– 480. http://dx.doi
.org/10.1111/j.1574-695X.2012.00978.x.
52. Ogawa T, Hashikawa S, Asai Y, Sakamoto H, Yasuda K, Makimura
Y. 2006. A new synbiotic, Lactobacillus casei subsp. casei together with
dextran, reduces murine and human allergic reaction. FEMS Immunol
Med Microbiol 46:400 – 409. http://dx.doi.org/10.1111/j.1574-695X
.2006.00046.x.
53. Piva A, Casadei G, Gatta PP, Luchansky JB, Biagi G. 2005. Effect of
lactitol, lactic acid bacteria, or their combinations (synbiotic) on intestinal
proteolysis in vitro, and on feed efficiency in weaned pigs. Can J Anim Sci
85:345–353. http://dx.doi.org/10.4141/A04-087.
54. Bird AR, Vuaran M, Crittenden R, Hayakawa T, Playne MJ, Brown IL,
Topping DL. 2009. Comparative effects of a high-amylose starch and a
fructooligosaccharide on fecal bifidobacteria numbers and short-chain
fatty acids in pigs fed Bifidobacterium animalis. Dig Dis Sci 54:947–954.
http://dx.doi.org/10.1007/s10620-008-0451-3.
55. Böhmer BM, Branner GR, Roth-Maier DA. 2005. Precaecal and faecal digest-
ibility of inulin (DP 10-12) or an inulin/Enterococcus faecium mix and effects on
nutrient digestibility and microbial gut flora. J Anim Physiol Anim Nutr (Berl)
89:388–396. http://dx.doi.org/10.1111/j.1439-0396.2005.00530.x.
56. Bomba A, Nemcová R, Gancarcíková S, Herich R, Guba P, Mudronová D.
2002. Improvement of the probiotic effect of micro-organisms by their combina-
tion with maltodextrins, fructo-oligosaccharides and polyunsaturated fatty acids.
Br J Nutr 88(Suppl 1):S95–S99. http://dx.doi.org/10.1079/BJN2002634.
57. Shim SB, Verstegen MWA, Kim IH, Kwon OS, Verdonk JMAJ. 2005.
Effects of feeding antibiotic-free creep feed supplemented with oligofruc-
tose, probiotics or synbiotics to suckling piglets increases the preweaning
weight gain and composition of intestinal microbiota. Arch Anim Nutr
59:419 – 427. http://dx.doi.org/10.1080/17450390500353234.
58. Baffoni L, Gaggìa F, Di Gioia D, Santini C, Mogna L, Biavati B. 2012.
A Bifidobacterium-based synbiotic product to reduce the transmission of
C. jejuni along the poultry food chain. Int J Food Microbiol 157:156 –161.
http://dx.doi.org/10.1016/j.ijfoodmicro.2012.04.024.
59. Abdel-Raheem S, Abd-Allah S, Hassanein K. 2012. The effects of prebi-
otic, probiotic and synbiotic supplementation on intestinal microbial
ecology and histomorphology of broiler chickens. Int J Agro Vet Med Sci
6:277–289. http://dx.doi.org/10.5455/ijavms.156.
60. Furrie E, Macfarlane S, Kennedy A, Cummings JH, Walsh SV, O’Neil
DA, Macfarlane GT. 2005. Synbiotic therapy (Bifidobacterium longum/
Synergy 1) initiates resolution of inflammation in patients with active
ulcerative colitis: a randomised controlled pilot trial. Gut 54:242–249.
http://dx.doi.org/10.1136/gut.2004.044834.
61. Gopal PK, Prasad J, Gill HS. 2003. Effects of the consumption of Bifido-
bacterium lactis HN019 (DR10) and galacto-oligosaccharides on the mi-
croflora of the gastrointestinal tract in human subjects. Nutr Res 23:1313–
1328. http://dx.doi.org/10.1016/S0271-5317(03)00134-9.
62. Schultz M, Munro K, Tannock GW, Melchner I, Göttl C, Schwietz H,
Schölmerich J, Rath HC. 2004. Effects of feeding a probiotic preparation
(SIM) containing inulin on the severity of colitis and on the composition of
the intestinal microflora in HLA-B27 transgenic rats. Clin Diagn Lab Immu-
nol 11:581–587. http://dx.doi.org/10.1128/CDLI.11.3.581-587.2004.
63. Nakanishi S, Kataoka K, Kuwahara T, Ohnishi Y. 2003. Effects of high
amylose maize starch and Clostridium butyricum on metabolism in co-
lonic microbiota and formation of azoxymethane-induced aberrant crypt
foci in the rat colon. Microbiol Immunol 47:951–958. http://dx.doi.org/10
.1111/j.1348-0421.2003.tb03469.x.
64. Krause DO, Bhandari SK, House JD, Nyachoti CM. 2010. Response of
nursery pigs to a synbiotic preparation of starch and an anti-Escherichia
coli K88 probiotic. Appl Environ Microbiol 76:8192– 8200. http://dx.doi
.org/10.1128/AEM.01427-10.
65. Stecher B, Hardt W-D. 2008. The role of microbiota in infectious disease.
Trends Microbiol 16:107–114. http://dx.doi.org/10.1016/j.tim.2007.12
.008.
66. Kalliomäki M, Collado MC, Salminen S, Isolauri E. 2008. Early differ-
ences in fecal microbiota composition in children may predict overweight.
Am J Clin Nutr 87:534 –538.
67. Ewaschuk JB, Diaz H, Meddings L, Diederichs B, Dmytrash A, Backer
J, Looijer-van Langen M, Madsen KL. 2008. Secreted bioactive factors
from Bifidobacterium infantis enhance epithelial cell barrier function. Am
J Physiol Gastrointest Liver Physiol 295:G1025–G1034. http://dx.doi.org
/10.1152/ajpgi.90227.2008.
68. Wang Z, Xiao G, Yao Y, Guo S, Lu K, Sheng Z. 2006. The role of
bifidobacteria in gut barrier function after thermal injury in rats. J Trauma
61:650 – 657. http://dx.doi.org/10.1097/01.ta.0000196574.70614.27.
69. Mitsuoka T. 1990. Bifidobacteria and their role in human health. J Ind
Microbiol 6:263–267. http://dx.doi.org/10.1007/BF01575871.
70. Petrof EO, Khoruts A. 2014. From stool transplants to next-generation
microbiota therapeutics. Gastroenterology 146:1573–1582. http://dx.doi
.org/10.1053/j.gastro.2014.01.004.
71. Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, Tobe
T, Clarke JM, Topping DL, Suzuki T, Taylor TD, Itoh K, Kikuchi J,
Morita H, Hattori M, Ohno H. 2011. Bifidobacteria can protect from
enteropathogenic infection through production of acetate. Nature 469:
543–547. http://dx.doi.org/10.1038/nature09646.
72. Maathuis AJH, van den Heuvel EG, Schoterman MHC, Venema K.
2012. Galacto-oligosaccharides have prebiotic activity in a dynamic in
vitro colon model using a (13)C-labeling technique. J Nutr 142:1205–
1212. http://dx.doi.org/10.3945/jn.111.157420.
73. Liu C, Finegold SM, Song Y, Lawson PA. 2008. Reclassification of
Clostridium coccoides, Ruminococcus hansenii, Ruminococcus hydrog-
enotrophicus, Ruminococcus luti, Ruminococcus productus and Rumi-
nococcus schinkii as Blautia coccoides gen. nov., comb. nov., Blautia han-
senii comb. nov., Blautia hydroge. Int J Syst Evol Microbiol 58:1896 –1902.
http://dx.doi.org/10.1099/ijs.0.65208-0.
74. De Vuyst L, Leroy F. 2011. Cross-feeding between bifidobacteria and
butyrate-producing colon bacteria explains bifdobacterial competitive-
ness, butyrate production, and gas production. Int J Food Microbiol 149:
73– 80. http://dx.doi.org/10.1016/j.ijfoodmicro.2011.03.003.
75. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB,
Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani
PD. 2013. Cross-talk between Akkermansia muciniphila and intestinal
epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A 110:
9066 –9071. http://dx.doi.org/10.1073/pnas.1219451110.
In Vivo Selection of a Synergistic Synbiotic
April 2015 Volume 81 Number 7 aem.asm.org 2465Applied and Environmental Microbiology
 
Table S1. Composition of standard and high-fat diets. 
Nutritional profile High-Fat Diet Standard Diet 
Protein [%] 24.2 17.6 
Fat [%] 34.7 5.2 
Fiber (max) [%] 5.5 3.9 
Carbohydrates [%] 27.8 68.3 
   
Energy (kcal/g) Kcal / % Kcal / % 
From Protein 0.969 / 18.6 0.705 / 18.3 
From Fat (ether extract) 3.122 / 59.9 0.464 / 12.1 
From Carbohydrates 1.113 / 21.4 2.733 / 71.0 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S2.  Body weight, relative epididymal fat pad weight, consumed drinking water, 
consumed IVS-1 and GOS, and host physiological markers.   
 Standard 
Diet 
High-Fat 
Diet 
High-Fat Diet 
Prebiotic 
High-Fat Diet 
Probiotic 
High-Fat 
Diet 
Synbiotic 
p - value 
ANOVA 
Average body 
weight [g rat
-1
] 
475 ±19 449 ±46 499 ±81 496 ±62 502 ±51 0.5446 
Average relative 
epididymal fat pad 
weight [% rat
-1
] 
0.84 ±0.2 1.04 ±0.4 1.12 ±0.3 1.01 ±0.2 1.08 ±0.5 0.8267 
Average water 
consumption [ml 
rat
-1
 day
-1
] 
29.3 ±4.1
b
 35.6 ±4.5
a
 36.3 ±4.9
a
 41.9 ±8.6
c
 35.4 ±4.5
a
 <0.0001 
Average IVS-1 
consumption [CFU 
rat
-1
 day
-1
] 
NA NA NA 1.26 x 10
9 a
 1.06 x 10
9 b
 0.0001
#
 
Average GOS 
consumption [g rat
-1
 
day
-1
] 
NA NA 1.20 NA 1.17 0.2063
#
 
Triglyceride content 
[µg TG mg
-1
 tissue] 
*
 
17.8 ±4.3
a
 70.7 ±1.4
b
 62.7 ±1.2
bc
 53.5 ±0.8
c
 92.4 ±2.4
d
 <0.0001 
Alkanine 
Phosphatase (ALP) 
[units liter
-1
] 
227 ±83 399 ±55 464 ±127 458 ±167 460 ±120 0.0646 
Alanine 
Transferase (ALT) 
[units liter
-1
] 
34 ±13 42 ±11 36 ±5 37±7 41 ±4 0.6418 
TNF-α [pg ml
-1
] 14.2 ±2.3 14.1 ±2.6 16.2 ±3.2 16.7 ±7.9 13.8 ±1.4 0.4718 
MCP-1 [pg ml
-1
] 224 ±25 228 ±37 239 ±21 248 ±63 243 ±36 0.6345 
* as a threshold for steatosis was a liver triglyceride levels greater than 50 µg/mg of tissue 
NA: not applicable 
# Student’s t-test was applied 
Values with different letters are significantly different from each other 
 
 
 
 
 
 
Figure S1.  Growth of B. adolescentis IVS-1 in basal MRS supplemented with GOS, 
0.16% lactose (residual sugar present in the commercial GOS), or basal MRS without 
carbohydrates.   
 
